Top Markets
Coin of the day
NeoImmuneTech, Inc. NeoImmuneTech, Inc.

NeoImmuneTech, Inc.

950220
Rank in Stocks #33504
As a clinical-stage biotechnology firm with a strong focus on T cells,... As a clinical-stage biotechnology firm with a strong focus on T cells, NeoImmuneTech, Inc. is dedicated to creating and marketing innovative immunotherapies. The company's lead product, NT-I7, is a long-acting human IL-7 currently in clinical development for its potential to treat a range of oncologic and infectious conditions. Founded in 2014, NeoImmuneTech is based in Rockville, Maryland.
Share Price
$1.12
Last synced: 2026-08-14
Market Cap
$7.52M
Change (1 day)
4.51%
Change (1 year)
-94.79%
Country
US
Trade NeoImmuneTech, Inc. (950220)

Category

Revenue for NeoImmuneTech, Inc. (950220)
Revenue in Aug 2026 TTM: 0
According to NeoImmuneTech, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for NeoImmuneTech, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$12.62B -
US
$6.02B -
NL
- -
CH
- -
KR
$10.11B -
BE